Efficacy of the four weeks treatment of omeprazole plus mosapride combination therapy compared with that of omeprazole monotherapy in patients with proton pump inhibitor-refractory gastroesophageal reflux disease: a randomized controlled trial

References

• Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920. doi:10.1111/j.1572-0241.2006.00630.x16928254
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–880. doi:10.1136/gutjnl-2012-30426923853213
   PubMed Web of Science ®Google Scholar
• Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil. 2011;17:14–27. doi:10.5056/jnm.2011.17.1.1421369488
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086–2100. doi:10.1016/S0140-6736(06)68932-016798392
   PubMed Web of Science ®Google Scholar
• Hsu PI, Lu CL, Wu DC, et al. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis. Clin Gastroenterol Hepatol. 2015;13:859–866. doi:10.1016/j.cgh.2014.09.03325245625
   PubMed Web of Science ®Google Scholar
• Fock KM, Talley N, Goh KL, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut. 2016;65:1402–1415. doi:10.1136/gutjnl-2016-31171527261337
   PubMed Web of Science ®Google Scholar
• Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep. 2008;10:252–257.18625135
   PubMedGoogle Scholar
• Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106–1110. doi:10.1056/NEJM1995102633317037565948
   PubMed Web of Science ®Google Scholar
• Carlsson L, Amos GJ, Andersson B, et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther. 1997;282:220–227.9223557
   PubMed Web of Science ®Google Scholar
• Potet F, Bouyssou T, Escande D, Baró I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. J Pharmacol Exp Ther. 2001;299:1007–1012.11714889
   PubMed Web of Science ®Google Scholar
• Ruth M, Hamelin B, Röhss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1998;12:35–40.9692698
   PubMed Web of Science ®Google Scholar
• Futagami S, Iwakiri K, Shindo T, et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol. 2010;45:413–421. doi:10.1007/s00535-009-0173-019997942
   PubMed Web of Science ®Google Scholar
• Madan K, Ahuja V, Kashyap PC, Sharma MP. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus. 2004;17:274–278. doi:10.1111/j.1442-2050.2004.00424.x15569362
   PubMed Web of Science ®Google Scholar
• Liu Q, Feng CC, Wang EM, Yan XJ, Chen SL. Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic review. World J Gastroenterol. 2013;19:9111–9118. doi:10.3748/wjg.v19.i47.911124379638
   PubMed Web of Science ®Google Scholar
• Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888–891. doi:10.1007/s00535-004-1417-715565409
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Manabe N, Haruma K. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy. Intern Med. 2010;49:1469–1476. doi:10.2169/internalmedicine.49.361520686276
   PubMed Web of Science ®Google Scholar
• Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–180. doi:10.1136/gut.45.2.17210403727
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Kim HC, Pandolfino JE. Approaches to the diagnosis and grading of hiatal hernia. Best Pract Res Clin Gastroenterol. 2008;22:601–616. doi:10.1016/j.bpg.2007.12.00718656819
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Haruma K, Takeuchi K, Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol. 2008;23:746–751. doi:10.1111/j.1440-1746.2007.05218.x18028348
   PubMed Web of Science ®Google Scholar
• Hsu YC, Yang TH, Hsu WL, et al. Mosapride as an adjunct to lansoprazole for symptom relief of reflux oesophagitis. Br J Clin Pharmacol. 2010;70:171–179. doi:10.1111/j.1365-2125.2010.03696.x20653670
   PubMed Web of Science ®Google Scholar
• Goh KL. Gastroesophageal reflux disease in Asia: a historical perspective and present challenges. J Gastroenterol Hepatol. 2011;26(Suppl 1):2–10. doi:10.1111/j.1440-1746.2010.06534.x
   Web of Science ®Google Scholar
• Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther. 2005;22:79–94. doi:10.1111/j.1365-2036.2005.02531.x
   PubMed Web of Science ®Google Scholar
• Arai K, Takeuchi Y, Watanabe H, et al. Prokinetics influence the pharmacokinetics of rabeprazole. Digestion. 2008;78:67–71. doi:10.1159/00016535118948689
   PubMed Web of Science ®Google Scholar
• Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017;29:1–15. doi:10.1111/nmo.13067
   PubMed Web of Science ®Google Scholar